Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A 779 TFA is a potent antagonist of angiotensin-(1-7) receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 50.00 | |
5 mg | In stock | $ 62.00 | |
10 mg | In stock | $ 92.00 | |
25 mg | In stock | $ 167.00 | |
50 mg | In stock | $ 250.00 | |
100 mg | In stock | $ 375.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 139.00 |
Description | A 779 TFA is a potent antagonist of angiotensin-(1-7) receptor. |
In vitro | A-779 suppresses the proliferating cell nuclear antigen (PCNA) protein expression up-regulated by Ang II, but A-779 alone has no effect to induce proliferation and migration of VSMCs.?Pretreatment with Ang-(1-7) significantly retards Ang II-induced inflammatory responses of VSMCs associated with up-regulated MCP-1, VCAM-1 and IL-1β expressions, and this effect of Ang-(1-7) is blocked by A-779.?But A-779 alone has no effect to induce inflammatory response of VSMCs[1]. |
In vivo | Inhibition of Ang1-7 cascade by A-779 significantly eradicated captopril protective effects on bone metabolism, mineralization and micro-structure.?A-779 also restored OVX effects on RANKL expression and ACE-1/AngII/AT1R cascade and down-regulated OPG expression and ACE-2/Ang1-7/Mas pathway.?In line with the clinical observations of the bone-preservative properties following ACE-1 inhibition, local activation of ACE-2/Ang1-7/Mas signaling and suppressed osteoclastogenesis seem responsible for the osteo-preservative effect of captopril, which could offers a potential therapeutic value in treatment of disabling bone and skeletal muscular diseases[2]. |
Cell Research | HUVECs were cultured in vitro and divided into six groups:?the control group (normal medium), the ox-LDL group(treated with 75 mg/L ox-LDL), the ox-LDL+ Ang-(1-7) group (1 μmol/L Ang-(1-7) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL), the ox-LDL+ Ang-(1-7)+ A-779 group(1 μmol/L A-779 (Mas receptor) pretreated for 30 minutes, 1 μmol/L Ang-(1-7) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL), the ox-LDL+ A-779 group (1 μmol/L A-779 pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL),?the ox-LDL+ HTA125 group (10 μg/L HTA125 (TLR4-blocking antibody) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL ).?The corresponding index was detected after 24 hours after intervention.?Apoptosis of cells were detected by Annexin V-FITC/PI double staining flow cytometry and transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL).?The generation of reactive oxygen species (ROS), products in oxidative stress, were detected by DCFH-DA staining.?The mRNA and protein expression levels of NADPH oxidase 4(NOX4) and TLR4 were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting analysis respectively[1]. |
Synonyms | A 779 3TFA(159432-28-7(free base)) |
Molecular Weight | 987.01 |
Formula | C41H61F3N12O13 |
CAS No. | T7616L |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9.87 mg/mL (10 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
A 779 TFA(159432-28-7 free base) T7616L Endocrinology/Hormones RAAS A 779 3TFA(159432-28-7(free base)) A 779 TFA(159432 28 7 free base) A 779 TFA(159432287 free base) inhibitor inhibit